Pyridium
Phase 3Small molecule
Pyridium is one of 6 small molecule programs targeting Dysuria. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Dysuria
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Methylthioninium Chloride
PProvepharm SAS
Approved
Azo-Standard
UUniversity of Massachusetts, Worcester
Phase 3
Pyridium
TTexas Tech University Health Sciences Center
Phase 3
Tamsulosin OCAS
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dysuria1 trial
Intraoperative1 trial
CAR1 trial
Evaluation of Ureteral Patency in the Post-indigo Carmine Era
Completed·—·Phase 4·NCT02677623·140 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pyridium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details